Trimbow MDI
Indication
Maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta 2-agonist
Green (Restricted)
Brand:
Trimbow®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Respiratory system
Background
Beclometasone / formoterol / glycopyrronium bromide pressurised metered dose inhaler (Trimbow®) is recommended as an option for the treatment of COPD with the following restriction:
Triple therapy should be reserved for patients who have failed to achieve or maintain an adequate response to an appropriate course of dual therapy.
Recommendation
LSCMMG Recommendation:
Green (Restricted)
Reason for decision:
Suitable for initiation in primary care in line with restrictions
Supporting documents: